drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00960 | DB06705 | 887 | 1,106 | [
"DDInter1471",
"DDInter795"
] | Pindolol | Gadofosveset trisodium | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of th... | Moderate | 1 | [
[
[
887,
24,
1106
]
],
[
[
887,
63,
457
],
[
457,
40,
1106
]
],
[
[
887,
24,
796
],
[
796,
40,
1106
]
],
[
[
887,
21,
28644
],
[
28644,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadofosveset trisodium (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid and Gadoxetic acid (Compound) resembles Gado... |
DB00704 | DB00722 | 267 | 743 | [
"DDInter1263",
"DDInter1079"
] | Naltrexone | Lisinopril | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
267,
24,
743
]
],
[
[
267,
63,
610
],
[
610,
40,
743
]
],
[
[
267,
24,
954
],
[
954,
40,
743
]
],
[
[
267,
63,
1638
],
[
1638,
1... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Lisinopril (Compound)
Nalt... |
DB08816 | DB08932 | 578 | 1,398 | [
"DDInter1802",
"DDInter1111"
] | Ticagrelor | Macitentan | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
578,
24,
1398
]
],
[
[
578,
6,
8374
],
[
8374,
45,
1398
]
],
[
[
578,
21,
28666
],
[
28666,
60,
1398
]
],
[
[
578,
24,
283
],
[
283,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ticagrelor",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Ticagrelor (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound)
Ticagrelor (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Macitentan (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when ta... |
DB00673 | DB06772 | 723 | 310 | [
"DDInter112",
"DDInter259"
] | Aprepitant | Cabazitaxel | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
723,
24,
310
]
],
[
[
723,
24,
973
],
[
973,
24,
310
]
],
[
[
723,
6,
7524
],
[
7524,
45,
310
]
],
[
[
723,
21,
28692
],
[
28692,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Aprepitant (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Aprepitant (Comp... |
DB06589 | DB09143 | 1,250 | 313 | [
"DDInter1400",
"DDInter1701"
] | Pazopanib | Sonidegib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
1250,
24,
313
]
],
[
[
1250,
64,
1194
],
[
1194,
23,
313
]
],
[
[
1250,
64,
478
],
[
478,
24,
313
]
],
[
[
1250,
24,
1478
],
[
1478,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
... | Pazopanib may lead to a major life threatening interaction when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Pazopanib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction... |
DB00860 | DB01064 | 891 | 1,148 | [
"DDInter1513",
"DDInter987"
] | Prednisolone | Isoprenaline | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Minor | 0 | [
[
[
891,
23,
1148
]
],
[
[
891,
23,
480
],
[
480,
24,
1148
]
],
[
[
891,
63,
1523
],
[
1523,
24,
1148
]
],
[
[
891,
24,
887
],
[
887,
... | [
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
],
[
... | Prednisolone may cause a minor interaction that can limit clinical effects when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Lab... |
DB00169 | DB06410 | 386 | 1,196 | [
"DDInter367",
"DDInter595"
] | Cholecalciferol | Doxercalciferol | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Major | 2 | [
[
[
386,
25,
1196
]
],
[
[
386,
23,
1142
],
[
1142,
23,
1196
]
],
[
[
386,
24,
359
],
[
359,
24,
1196
]
],
[
[
386,
24,
853
],
[
853,
... | [
[
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Cholecalciferol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
],
[
... | Cholecalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide... |
DB08880 | DB11952 | 1,510 | 800 | [
"DDInter1771",
"DDInter612"
] | Teriflunomide | Duvelisib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
1510,
25,
800
]
],
[
[
1510,
24,
466
],
[
466,
62,
800
]
],
[
[
1510,
64,
310
],
[
310,
24,
800
]
],
[
[
1510,
25,
1476
],
[
1476,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Dar... | Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Teriflunomide may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel m... |
DB01229 | DB08913 | 973 | 1,186 | [
"DDInter1377",
"DDInter1561"
] | Paclitaxel | Radium Ra 223 dichloride | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
973,
24,
1186
]
],
[
[
973,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
973,
63,
134
],
[
134,
24,
1186
]
],
[
[
973,
24,
1491
],
[
1491,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u}... | Paclitaxel (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases... |
DB11627 | DB14762 | 1,367 | 994 | [
"DDInter860",
"DDInter1602"
] | Hepatitis B Vaccine (Recombinant) | Risankizumab | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
1367,
24,
994
]
],
[
[
1367,
63,
4
],
[
4,
24,
994
]
],
[
[
1367,
24,
270
],
[
270,
24,
994
]
],
[
[
1367,
24,
676
],
[
676,
64,... | [
[
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when tak... | Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Hepatitis B Vaccine (Recombinant) may cause a moderate in... |
DB00372 | DB00494 | 999 | 1,533 | [
"DDInter1793",
"DDInter646"
] | Thiethylperazine | Entacapone | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | Moderate | 1 | [
[
[
999,
24,
1533
]
],
[
[
999,
63,
1062
],
[
1062,
1,
1533
]
],
[
[
999,
24,
770
],
[
770,
63,
1533
]
],
[
[
999,
24,
128
],
[
128,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interactio... |
DB00054 | DB08896 | 1,432 | 292 | [
"DDInter6",
"DDInter1576"
] | Abciximab | Regorafenib | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1432,
25,
292
]
],
[
[
1432,
24,
643
],
[
643,
24,
292
]
],
[
[
1432,
24,
41
],
[
41,
63,
292
]
],
[
[
1432,
25,
553
],
[
553,
2... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenl... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipra... |
DB01100 | DB12500 | 1,568 | 283 | [
"DDInter1470",
"DDInter714"
] | Pimozide | Fedratinib | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1568,
25,
283
]
],
[
[
1568,
25,
351
],
[
351,
23,
283
]
],
[
[
1568,
64,
1419
],
[
1419,
24,
283
]
],
[
[
1568,
24,
951
],
[
951,
... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may c... | Pimozide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Pimozide may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction th... |
DB00009 | DB01125 | 1,271 | 279 | [
"DDInter56",
"DDInter98"
] | Alteplase | Anisindione | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Major | 2 | [
[
[
1271,
25,
279
]
],
[
[
1271,
24,
1595
],
[
1595,
24,
279
]
],
[
[
1271,
24,
557
],
[
557,
63,
279
]
],
[
[
1271,
25,
1564
],
[
1564,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
]... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Alteplase may cause a moderate interaction that could exacer... |
DB01064 | DB12332 | 1,148 | 1,619 | [
"DDInter987",
"DDInter1626"
] | Isoprenaline | Rucaparib | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1148,
24,
1619
]
],
[
[
1148,
24,
222
],
[
222,
23,
1619
]
],
[
[
1148,
63,
307
],
[
307,
23,
1619
]
],
[
[
1148,
63,
87
],
[
87,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Moda... |
DB08827 | DB11967 | 990 | 710 | [
"DDInter1085",
"DDInter210"
] | Lomitapide | Binimetinib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Major | 2 | [
[
[
990,
25,
710
]
],
[
[
990,
25,
1593
],
[
1593,
24,
710
]
],
[
[
990,
24,
951
],
[
951,
24,
710
]
],
[
[
990,
64,
883
],
[
883,
2... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} ... | Lomitapide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cau... |
DB00365 | DB11581 | 839 | 1,456 | [
"DDInter842",
"DDInter1926"
] | Grepafloxacin | Venetoclax | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
839,
24,
1456
]
],
[
[
839,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
839,
24,
86
],
[
86,
24,
1456
]
],
[
[
839,
25,
982
],
[
982,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and ... |
DB00414 | DB01001 | 590 | 688 | [
"DDInter16",
"DDInter1632"
] | Acetohexamide | Salbutamol | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
590,
24,
688
]
],
[
[
590,
24,
874
],
[
874,
24,
688
]
],
[
[
590,
63,
1636
],
[
1636,
24,
688
]
],
[
[
590,
24,
1148
],
[
1148,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine... |
DB01001 | DB01577 | 688 | 1,529 | [
"DDInter1632",
"DDInter1161"
] | Salbutamol | Metamfetamine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Moderate | 1 | [
[
[
688,
24,
1529
]
],
[
[
688,
63,
939
],
[
939,
40,
1529
]
],
[
[
688,
24,
1161
],
[
1161,
40,
1529
]
],
[
[
688,
24,
93
],
[
93,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Metamfetamine... |
DB08880 | DB09121 | 1,510 | 1,328 | [
"DDInter1771",
"DDInter140"
] | Teriflunomide | Aurothioglucose | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Major | 2 | [
[
[
1510,
25,
1328
]
],
[
[
1510,
64,
367
],
[
367,
24,
1328
]
],
[
[
1510,
25,
375
],
[
375,
24,
1328
]
],
[
[
1510,
63,
10
],
[
10,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon alfacon-1"
],
[
"Inte... | Teriflunomide may lead to a major life threatening interaction when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Teriflunomide may lead to a major life threatening interaction when taken with Certolizumab pegol a... |
DB00332 | DB03128 | 1,089 | 140 | [
"DDInter970",
"DDInter18"
] | Ipratropium | Acetylcholine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken ... | Moderate | 1 | [
[
[
1089,
24,
140
]
],
[
[
1089,
24,
1376
],
[
1376,
24,
140
]
],
[
[
1089,
63,
352
],
[
352,
24,
140
]
],
[
[
1089,
24,
1116
],
[
1116,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylcholine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospi... |
DB00980 | DB12130 | 969 | 1,017 | [
"DDInter1564",
"DDInter1094"
] | Ramelteon | Lorlatinib | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
969,
24,
1017
]
],
[
[
969,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
969,
24,
214
],
[
214,
24,
1017
]
],
[
[
969,
24,
159
],
[
159,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamat... |
DB00214 | DB11113 | 1,028 | 657 | [
"DDInter1836",
"DDInter307"
] | Torasemide | Castor oil | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1028,
24,
657
]
],
[
[
1028,
24,
891
],
[
891,
24,
657
]
],
[
[
1028,
24,
1019
],
[
1019,
63,
657
]
],
[
[
1028,
63,
600
],
[
600,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and D... |
DB00880 | DB06655 | 359 | 5 | [
"DDInter360",
"DDInter1077"
] | Chlorothiazide | Liraglutide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
359,
24,
5
]
],
[
[
359,
63,
870
],
[
870,
24,
5
]
],
[
[
359,
24,
480
],
[
480,
24,
5
]
],
[
[
359,
40,
1326
],
[
1326,
24,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Fo... |
DB00450 | DB01041 | 78 | 770 | [
"DDInter603",
"DDInter1789"
] | Droperidol | Thalidomide | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
78,
24,
770
]
],
[
[
78,
21,
28789
],
[
28789,
60,
770
]
],
[
[
78,
25,
609
],
[
609,
63,
770
]
],
[
[
78,
25,
1557
],
[
1557,
2... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"... | Droperidol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Droperidol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when ... |
DB00030 | DB00397 | 1,685 | 1,466 | [
"DDInter934",
"DDInter1458"
] | Insulin human | Phenylpropanolamine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Moderate | 1 | [
[
[
1685,
24,
1466
]
],
[
[
1685,
24,
73
],
[
73,
25,
1466
]
],
[
[
1685,
24,
1178
],
[
1178,
63,
1466
]
],
[
[
1685,
24,
1152
],
[
1152,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and... |
DB00041 | DB00404 | 1,648 | 523 | [
"DDInter38",
"DDInter54"
] | Aldesleukin | Alprazolam | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Moderate | 1 | [
[
[
1648,
24,
523
]
],
[
[
1648,
24,
1418
],
[
1418,
40,
523
]
],
[
[
1648,
24,
1382
],
[
1382,
1,
523
]
],
[
[
1648,
24,
891
],
[
891,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Alprazolam (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Alprazolam (Compound)
Al... |
DB00792 | DB01100 | 832 | 1,568 | [
"DDInter1878",
"DDInter1470"
] | Tripelennamine | Pimozide | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
832,
24,
1568
]
],
[
[
832,
63,
78
],
[
78,
40,
1568
]
],
[
[
832,
6,
12523
],
[
12523,
45,
1568
]
],
[
[
832,
63,
19
],
[
19,
2... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Tripelennamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pimozide (Compound)
Tripelennamine may cause a moderate interaction that could exa... |
DB01041 | DB09118 | 770 | 1,580 | [
"DDInter1789",
"DDInter1711"
] | Thalidomide | Stiripentol | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
770,
24,
1580
]
],
[
[
770,
63,
168
],
[
168,
24,
1580
]
],
[
[
770,
25,
1532
],
[
1532,
24,
1580
]
],
[
[
770,
24,
1609
],
[
1609,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cau... |
DB00692 | DB09038 | 274 | 1,450 | [
"DDInter1448",
"DDInter636"
] | Phentolamine | Empagliflozin | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
274,
24,
1450
]
],
[
[
274,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
274,
24,
885
],
[
885,
24,
1450
]
],
[
[
274,
62,
1179
],
[
1179,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprosten... |
DB00526 | DB00862 | 1,555 | 1,005 | [
"DDInter1355",
"DDInter1918"
] | Oxaliplatin | Vardenafil | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Moderate | 1 | [
[
[
1555,
24,
1005
]
],
[
[
1555,
24,
112
],
[
112,
63,
1005
]
],
[
[
1555,
63,
1494
],
[
1494,
24,
1005
]
],
[
[
1555,
24,
522
],
[
522,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vardenafil"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron ... |
DB01076 | DB06273 | 700 | 980 | [
"DDInter133",
"DDInter1824"
] | Atorvastatin | Tocilizumab | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
700,
24,
980
]
],
[
[
700,
24,
309
],
[
309,
24,
980
]
],
[
[
700,
24,
850
],
[
850,
63,
980
]
],
[
[
700,
63,
467
],
[
467,
24,... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab ve... |
DB00092 | DB06616 | 58 | 594 | [
"DDInter40",
"DDInter224"
] | Alefacept | Bosutinib | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
58,
24,
594
]
],
[
[
58,
24,
713
],
[
713,
63,
594
]
],
[
[
58,
24,
663
],
[
663,
24,
594
]
],
[
[
58,
63,
599
],
[
599,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Methotrexa... |
DB01234 | DB11936 | 1,220 | 1,030 | [
"DDInter513",
"DDInter176"
] | Dexamethasone | Bempedoic acid | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with el... | Major | 2 | [
[
[
1220,
25,
1030
]
],
[
[
1220,
63,
473
],
[
473,
24,
1030
]
],
[
[
1220,
24,
1450
],
[
1450,
24,
1030
]
],
[
[
1220,
1,
891
],
[
891,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Empaglifl... |
DB00889 | DB14723 | 1,133 | 159 | [
"DDInter840",
"DDInter1026"
] | Granisetron | Larotrectinib | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1133,
24,
159
]
],
[
[
1133,
25,
222
],
[
222,
23,
159
]
],
[
[
1133,
63,
479
],
[
479,
23,
159
]
],
[
[
1133,
64,
1230
],
[
1230,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibu... | Granisetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cau... |
DB01177 | DB11791 | 77 | 785 | [
"DDInter904",
"DDInter287"
] | Idarubicin | Capmatinib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
77,
24,
785
]
],
[
[
77,
25,
868
],
[
868,
24,
785
]
],
[
[
77,
63,
482
],
[
482,
24,
785
]
],
[
[
77,
74,
322
],
[
322,
24,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafen... | Idarubicin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may caus... |
DB00814 | DB06603 | 1,171 | 39 | [
"DDInter1143",
"DDInter1387"
] | Meloxicam | Panobinostat | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1171,
25,
39
]
],
[
[
1171,
63,
912
],
[
912,
24,
39
]
],
[
[
1171,
24,
578
],
[
578,
63,
39
]
],
[
[
1171,
25,
4
],
[
4,
24,
... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"In... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Ticag... |
DB00218 | DB01050 | 1,176 | 848 | [
"DDInter1247",
"DDInter900"
] | Moxifloxacin | Ibuprofen | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1176,
24,
848
]
],
[
[
1176,
23,
1053
],
[
1053,
1,
848
]
],
[
[
1176,
21,
28773
],
[
28773,
60,
848
]
],
[
[
1176,
24,
286
],
[
286,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
],
[... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Moxifloxacin (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Ibuprofen (Compound)
Moxifloxacin may cause a... |
DB00196 | DB00726 | 600 | 1,164 | [
"DDInter743",
"DDInter1876"
] | Fluconazole | Trimipramine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
600,
24,
1164
]
],
[
[
600,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
600,
25,
576
],
[
576,
40,
1164
]
],
[
[
600,
6,
6017
],
[
6017,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Trimipramine (Compound)
Flucona... |
DB00352 | DB05273 | 482 | 507 | [
"DDInter1814",
"DDInter1638"
] | Tioguanine | Samarium (153Sm) lexidronam | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
482,
25,
507
]
],
[
[
482,
24,
248
],
[
248,
24,
507
]
],
[
[
482,
24,
270
],
[
270,
63,
507
]
],
[
[
482,
63,
1101
],
[
1101,
2... | [
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB11363 | DB14730 | 1,276 | 1,412 | [
"DDInter39",
"DDInter264"
] | Alectinib | Calaspargase pegol | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1276,
24,
1412
]
],
[
[
1276,
63,
322
],
[
322,
24,
1412
]
],
[
[
1276,
63,
770
],
[
770,
25,
1412
]
],
[
[
1276,
64,
1377
],
[
1377,
... | [
[
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and... |
DB00661 | DB09340 | 122 | 1,013 | [
"DDInter1928",
"DDInter1895"
] | Verapamil | Tyropanoic acid | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
122,
24,
1013
]
],
[
[
122,
24,
1431
],
[
1431,
24,
1013
]
],
[
[
122,
63,
1648
],
[
1648,
24,
1013
]
],
[
[
122,
24,
1431
],
[
1431,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadopentetic acid"
]... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Gadopentetic acid and Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Alde... |
DB00427 | DB04908 | 1,233 | 1,671 | [
"DDInter1879",
"DDInter741"
] | Triprolidine | Flibanserin | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
1233,
24,
1671
]
],
[
[
1233,
24,
830
],
[
830,
24,
1671
]
],
[
[
1233,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
1233,
24,
407
],
[
407,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine a... |
DB00761 | DB01197 | 1,621 | 1,603 | [
"DDInter1497",
"DDInter292"
] | Potassium chloride | Captopril | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Major | 2 | [
[
[
1621,
25,
1603
]
],
[
[
1621,
64,
610
],
[
610,
1,
1603
]
],
[
[
1621,
21,
28766
],
[
28766,
60,
1603
]
],
[
[
1621,
62,
1179
],
[
117... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Captopril"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enalapril"
],
[
"Enalapril",... | Potassium chloride may lead to a major life threatening interaction when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Potassium chloride (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Captopril (Compound)
Potassium chloride may cause a minor intera... |
DB00550 | DB01193 | 99 | 819 | [
"DDInter1541",
"DDInter12"
] | Propylthiouracil | Acebutolol | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
99,
24,
819
]
],
[
[
99,
24,
887
],
[
887,
1,
819
]
],
[
[
99,
63,
88
],
[
88,
1,
819
]
],
[
[
99,
21,
29005
],
[
29005,
60,
... | [
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]... | Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Co... |
DB00342 | DB05294 | 1,181 | 1,069 | [
"DDInter1770",
"DDInter1917"
] | Terfenadine | Vandetanib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1181,
25,
1069
]
],
[
[
1181,
23,
1247
],
[
1247,
23,
1069
]
],
[
[
1181,
24,
659
],
[
659,
63,
1069
]
],
[
[
1181,
24,
688
],
[
688,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulf... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol ... |
DB01042 | DB01181 | 1,307 | 1,532 | [
"DDInter1144",
"DDInter906"
] | Melphalan | Ifosfamide | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1307,
24,
1532
]
],
[
[
1307,
5,
11555
],
[
11555,
44,
1532
]
],
[
[
1307,
54,
19138
],
[
19138,
15,
1532
]
],
[
[
1307,
21,
29209
],
[
... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Melphalan",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease)... | Melphalan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound)
Melphalan (Compound) causes Anorexia (S... |
DB00209 | DB11160 | 352 | 337 | [
"DDInter1886",
"DDInter1459"
] | Trospium | Phenyltoloxamine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
352,
24,
337
]
],
[
[
352,
24,
820
],
[
820,
24,
337
]
],
[
[
352,
35,
262
],
[
262,
24,
337
]
],
[
[
352,
25,
1621
],
[
1621,
2... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that coul... |
DB11718 | DB12141 | 927 | 971 | [
"DDInter640",
"DDInter817"
] | Encorafenib | Gilteritinib | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
927,
24,
971
]
],
[
[
927,
63,
1135
],
[
1135,
23,
971
]
],
[
[
927,
62,
1247
],
[
1247,
23,
971
]
],
[
[
927,
63,
485
],
[
485,
... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Encorafenib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Su... |
DB00712 | DB00731 | 1,274 | 1,144 | [
"DDInter763",
"DDInter1269"
] | Flurbiprofen | Nateglinide | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1274,
24,
1144
]
],
[
[
1274,
1,
11215
],
[
11215,
40,
1144
]
],
[
[
1274,
63,
610
],
[
610,
24,
1144
]
],
[
[
1274,
6,
1829
],
[
1829... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"L-Phenylalanine"
],
[
"L-Phenylalanine",
"{u} (Com... | Flurbiprofen (Compound) resembles L-Phenylalanine (Compound) and L-Phenylalanine (Compound) resembles Nateglinide (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00461 | DB08901 | 598 | 1,468 | [
"DDInter1254",
"DDInter1492"
] | Nabumetone | Ponatinib | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
598,
25,
1468
]
],
[
[
598,
18,
2060
],
[
2060,
46,
1468
]
],
[
[
598,
21,
29024
],
[
29024,
60,
1468
]
],
[
[
598,
23,
1194
],
[
1194... | [
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Nabumetone",
"{u} (Compound) downregulates {v} (Gene)",
"PIK3CA"
],
[
"PIK3CA",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Nabumetone (Compound) downregulates PIK3CA (Gene) and PIK3CA (Gene) is upregulated by Ponatinib (Compound)
Nabumetone (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound)
Nabumetone may cause a minor interaction that can limit clinical effects when taken with Ran... |
DB01259 | DB11652 | 392 | 1,155 | [
"DDInter1024",
"DDInter1891"
] | Lapatinib | Tucatinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
392,
25,
1155
]
],
[
[
392,
63,
222
],
[
222,
23,
1155
]
],
[
[
392,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
392,
24,
659
],
[
659,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine"... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may ... |
DB05679 | DB09052 | 1,683 | 250 | [
"DDInter1907",
"DDInter220"
] | Ustekinumab | Blinatumomab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
1683,
24,
250
]
],
[
[
1683,
24,
949
],
[
949,
63,
250
]
],
[
[
1683,
63,
305
],
[
305,
24,
250
]
],
[
[
1683,
24,
850
],
[
850,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxo... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Ustekinum... |
DB00008 | DB00188 | 491 | 168 | [
"DDInter1407",
"DDInter222"
] | Peginterferon alfa-2a | Bortezomib | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Moderate | 1 | [
[
[
491,
24,
168
]
],
[
[
491,
24,
126
],
[
126,
62,
168
]
],
[
[
491,
25,
1101
],
[
1101,
62,
168
]
],
[
[
491,
24,
1487
],
[
1487,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfa... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Bexarotene and Bexar... |
DB00496 | DB12010 | 194 | 214 | [
"DDInter480",
"DDInter785"
] | Darifenacin | Fostamatinib | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
194,
24,
214
]
],
[
[
194,
24,
723
],
[
723,
24,
214
]
],
[
[
194,
63,
600
],
[
600,
24,
214
]
],
[
[
194,
24,
1017
],
[
1017,
6... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and F... |
DB08931 | DB11986 | 947 | 484 | [
"DDInter1600",
"DDInter648"
] | Riociguat | Entrectinib | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
947,
24,
484
]
],
[
[
947,
24,
466
],
[
466,
62,
484
]
],
[
[
947,
24,
1320
],
[
1320,
24,
484
]
],
[
[
947,
63,
1478
],
[
1478,
... | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagoli... |
DB01069 | DB01142 | 401 | 1,264 | [
"DDInter1533",
"DDInter593"
] | Promethazine | Doxepin | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
401,
24,
1264
]
],
[
[
401,
74,
508
],
[
508,
24,
1264
]
],
[
[
401,
63,
832
],
[
832,
24,
1264
]
],
[
[
401,
1,
293
],
[
293,
4... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken ... | Promethazine (Compound) resembles Promazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promethazine may cause a moderate interaction that could... |
DB00460 | DB00759 | 612 | 1,620 | [
"DDInter1929",
"DDInter1783"
] | Verteporfin | Tetracycline | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
612,
24,
1620
]
],
[
[
612,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
612,
63,
964
],
[
964,
40,
1620
]
],
[
[
612,
24,
126
],
[
126,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Tetracyc... |
DB00060 | DB06210 | 912 | 72 | [
"DDInter947",
"DDInter631"
] | Interferon beta-1a | Eltrombopag | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
912,
24,
72
]
],
[
[
912,
24,
384
],
[
384,
63,
72
]
],
[
[
912,
24,
467
],
[
467,
24,
72
]
],
[
[
912,
63,
1560
],
[
1560,
24,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Simv... |
DB05812 | DB11652 | 1,374 | 1,155 | [
"DDInter8",
"DDInter1891"
] | Abiraterone | Tucatinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
1374,
25,
1155
]
],
[
[
1374,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
1374,
24,
659
],
[
659,
24,
1155
]
],
[
[
1374,
23,
466
],
[
466,
... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol ... |
DB00193 | DB00748 | 534 | 662 | [
"DDInter1841",
"DDInter297"
] | Tramadol | Carbinoxamine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
534,
24,
662
]
],
[
[
534,
24,
28
],
[
28,
40,
662
]
],
[
[
534,
24,
1594
],
[
1594,
24,
662
]
],
[
[
534,
6,
8374
],
[
8374,
45... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could ex... |
DB00346 | DB00526 | 472 | 1,555 | [
"DDInter44",
"DDInter1355"
] | Alfuzosin | Oxaliplatin | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
472,
24,
1555
]
],
[
[
472,
24,
79
],
[
79,
24,
1555
]
],
[
[
472,
24,
1213
],
[
1213,
63,
1555
]
],
[
[
472,
25,
384
],
[
384,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib ... |
DB09156 | DB09293 | 777 | 116 | [
"DDInter964",
"DDInter954"
] | Iopromide | Iodide I-131 | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
777,
24,
116
]
],
[
[
777,
24,
278
],
[
278,
63,
116
]
],
[
[
777,
64,
485
],
[
485,
24,
116
]
],
[
[
777,
25,
1399
],
[
1399,
6... | [
[
[
"Iopromide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iopromide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[
... | Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iopromide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may ... |
DB00316 | DB00619 | 474 | 1,419 | [
"DDInter14",
"DDInter909"
] | Acetaminophen | Imatinib | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the ... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
474,
24,
1419
]
],
[
[
474,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
474,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
474,
24,
1619
],
[
1619,... | [
[
[
"Acetaminophen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Acetaminophen",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Acetaminophen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Acetaminophen (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib ... |
DB01045 | DB01390 | 463 | 1,117 | [
"DDInter1590",
"DDInter1683"
] | Rifampicin | Sodium bicarbonate | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
463,
24,
1117
]
],
[
[
463,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
463,
63,
1573
],
[
1573,
23,
1117
]
],
[
[
463,
25,
263
],
[
263,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Prednison... |
DB00675 | DB01267 | 888 | 519 | [
"DDInter1744",
"DDInter1381"
] | Tamoxifen | Paliperidone | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
888,
24,
519
]
],
[
[
888,
24,
1664
],
[
1664,
1,
519
]
],
[
[
888,
25,
924
],
[
924,
1,
519
]
],
[
[
888,
6,
7524
],
[
7524,
45... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Tamoxifen... |
DB00446 | DB01073 | 597 | 1,488 | [
"DDInter351",
"DDInter745"
] | Chloramphenicol | Fludarabine | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
597,
24,
1488
]
],
[
[
597,
24,
1426
],
[
1426,
1,
1488
]
],
[
[
597,
21,
28725
],
[
28725,
60,
1488
]
],
[
[
597,
25,
975
],
[
975,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Fludarabine (Compound)
Chloramphenicol (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Fludarabine (Compound)
Chloramphenicol may lead... |
DB01105 | DB01144 | 222 | 1,326 | [
"DDInter1665",
"DDInter540"
] | Sibutramine | Diclofenamide | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
222,
24,
1326
]
],
[
[
222,
63,
504
],
[
504,
1,
1326
]
],
[
[
222,
63,
359
],
[
359,
40,
1326
]
],
[
[
222,
21,
28975
],
[
28975,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) r... |
DB00398 | DB01045 | 79 | 463 | [
"DDInter1702",
"DDInter1590"
] | Sorafenib | Rifampicin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
79,
24,
463
]
],
[
[
79,
24,
690
],
[
690,
40,
463
]
],
[
[
79,
6,
5912
],
[
5912,
45,
463
]
],
[
[
79,
18,
6665
],
[
6665,
57,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Sorafenib (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Rifampicin (Compound)
Sorafenib (Compound) downregulates TIMP1 (Gene) and TIMP1 (Gene) is down... |
DB00341 | DB01100 | 1,242 | 1,568 | [
"DDInter343",
"DDInter1470"
] | Cetirizine | Pimozide | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
1242,
24,
1568
]
],
[
[
1242,
40,
1413
],
[
1413,
40,
1568
]
],
[
[
1242,
24,
78
],
[
78,
40,
1568
]
],
[
[
1242,
6,
10104
],
[
10104,... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound)",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} (Compound) resemb... | Cetirizine (Compound) resembles Fexofenadine (Compound) and Fexofenadine (Compound) resembles Pimozide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Cetirizine (Compound) binds HRH1 (Gene) and HRH1... |
DB00193 | DB09104 | 534 | 286 | [
"DDInter1841",
"DDInter1118"
] | Tramadol | Magnesium hydroxide | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
534,
24,
286
]
],
[
[
534,
25,
820
],
[
820,
23,
286
]
],
[
[
534,
24,
752
],
[
752,
23,
286
]
],
[
[
534,
24,
688
],
[
688,
24,... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alim... | Tramadol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may c... |
DB00808 | DB00992 | 1,605 | 842 | [
"DDInter916",
"DDInter1182"
] | Indapamide | Methyl aminolevulinate (topical) | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
1605,
24,
842
]
],
[
[
1605,
21,
29360
],
[
29360,
60,
842
]
],
[
[
1605,
63,
1274
],
[
1274,
24,
842
]
],
[
[
1605,
24,
820
],
[
820,... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Indapamide",
"{u} (Compound) causes {v} (Side Effect)",
"Face oedema"
],
[
"Face oedema",
"{u} (Side... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Indapamide (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Methyl aminolevulinate (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases... |
DB00734 | DB11901 | 1,664 | 913 | [
"DDInter1605",
"DDInter107"
] | Risperidone | Apalutamide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1664,
24,
913
]
],
[
[
1664,
23,
112
],
[
112,
23,
913
]
],
[
[
1664,
63,
600
],
[
600,
24,
913
]
],
[
[
1664,
24,
28
],
[
28,
2... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and ... |
DB01170 | DB06764 | 1,150 | 1,090 | [
"DDInter846",
"DDInter1787"
] | Guanethidine | Tetryzoline (nasal) | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1150,
24,
1090
]
],
[
[
1150,
63,
1148
],
[
1148,
24,
1090
]
],
[
[
1150,
37,
247
],
[
247,
25,
1090
]
],
[
[
1150,
24,
1629
],
[
1629... | [
[
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
... |
DB01193 | DB01285 | 819 | 708 | [
"DDInter12",
"DDInter445"
] | Acebutolol | Corticotropin | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
819,
24,
708
]
],
[
[
819,
63,
455
],
[
455,
23,
708
]
],
[
[
819,
24,
659
],
[
659,
62,
708
]
],
[
[
819,
63,
245
],
[
245,
24,... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilan... |
DB00252 | DB00848 | 362 | 281 | [
"DDInter1460",
"DDInter1044"
] | Phenytoin | Levamisole | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Moderate | 1 | [
[
[
362,
24,
281
]
],
[
[
362,
24,
1683
],
[
1683,
63,
281
]
],
[
[
362,
24,
597
],
[
597,
24,
281
]
],
[
[
362,
63,
58
],
[
58,
24,... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamisole"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and C... |
DB01362 | DB06637 | 497 | 1,109 | [
"DDInter960",
"DDInter468"
] | Iohexol | Dalfampridine | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010. | Major | 2 | [
[
[
497,
25,
1109
]
],
[
[
497,
21,
28880
],
[
28880,
60,
1109
]
],
[
[
497,
64,
1645
],
[
1645,
24,
1109
]
],
[
[
497,
64,
593
],
[
593,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalfampridine"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Angiopathy"
],
[
"Angiopathy",
"{u} (Side Effect) is caused by {v} (Compo... | Iohexol (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Dalfampridine (Compound)
Iohexol may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Dalfampridine
Iohexol may... |
DB06043 | DB10343 | 1,644 | 962 | [
"DDInter1328",
"DDInter160"
] | Olaratumab | Bacillus calmette-guerin substrain tice live antigen | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1644,
25,
962
]
],
[
[
1644,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1644,
24,
270
],
[
270,
64,
962
]
],
[
[
1644,
24,
1362
],
[
1362,
... | [
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Olaratumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizum... |
DB01211 | DB11967 | 609 | 710 | [
"DDInter393",
"DDInter210"
] | Clarithromycin | Binimetinib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
609,
24,
710
]
],
[
[
609,
63,
441
],
[
441,
24,
710
]
],
[
[
609,
25,
1293
],
[
1293,
24,
710
]
],
[
[
609,
24,
1237
],
[
1237,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Clarithromycin may lead to a major life threatening interaction when taken with Valbenazine and Valbenazi... |
DB01589 | DB06691 | 481 | 849 | [
"DDInter1552",
"DDInter1155"
] | Quazepam | Mepyramine | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
481,
24,
849
]
],
[
[
481,
63,
1594
],
[
1594,
24,
849
]
],
[
[
481,
24,
1074
],
[
1074,
63,
849
]
],
[
[
481,
40,
1563
],
[
1563,
... | [
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I... |
DB01097 | DB11652 | 1,377 | 1,155 | [
"DDInter1033",
"DDInter1891"
] | Leflunomide | Tucatinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
1377,
25,
1155
]
],
[
[
1377,
64,
1101
],
[
1101,
23,
1155
]
],
[
[
1377,
25,
609
],
[
609,
24,
1155
]
],
[
[
1377,
64,
522
],
[
522,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} ... | Leflunomide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Leflunomide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a modera... |
DB00060 | DB00582 | 912 | 1,622 | [
"DDInter947",
"DDInter1946"
] | Interferon beta-1a | Voriconazole | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
912,
24,
1622
]
],
[
[
912,
24,
663
],
[
663,
24,
1622
]
],
[
[
912,
24,
1634
],
[
1634,
63,
1622
]
],
[
[
912,
63,
1560
],
[
1560,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrex... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00635 | DB08895 | 1,573 | 976 | [
"DDInter1515",
"DDInter1825"
] | Prednisone | Tofacitinib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1573,
25,
976
]
],
[
[
1573,
23,
307
],
[
307,
23,
976
]
],
[
[
1573,
23,
1193
],
[
1193,
62,
976
]
],
[
[
1573,
62,
1461
],
[
1461,
... | [
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Prednisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Prednisone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluc... |
DB00250 | DB00649 | 10 | 231 | [
"DDInter475",
"DDInter1710"
] | Dapsone | Stavudine | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
10,
24,
231
]
],
[
[
10,
24,
1477
],
[
1477,
40,
231
]
],
[
[
10,
24,
139
],
[
139,
1,
231
]
],
[
[
10,
21,
28810
],
[
28810,
60... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"T... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Stavudine (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Stavudine (Compound)
Dapson... |
DB01579 | DB09268 | 341 | 1,662 | [
"DDInter1439",
"DDInter1464"
] | Phendimetrazine | Picosulfuric acid | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
341,
24,
1662
]
],
[
[
341,
64,
73
],
[
73,
24,
1662
]
],
[
[
341,
63,
820
],
[
820,
24,
1662
]
],
[
[
341,
64,
73
],
[
73,
24,
... | [
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Phendimetrazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[... | Phendimetrazine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and A... |
DB01254 | DB08938 | 1,213 | 1,384 | [
"DDInter484",
"DDInter1112"
] | Dasatinib | Magaldrate | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1213,
24,
1384
]
],
[
[
1213,
63,
167
],
[
167,
23,
1384
]
],
[
[
1213,
64,
684
],
[
684,
23,
1384
]
],
[
[
1213,
24,
263
],
[
263,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Dasatinib may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine ma... |
DB11255 | DB13928 | 1,371 | 1,385 | [
"DDInter374",
"DDInter1660"
] | Chromium picolinate | Semaglutide | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1371,
24,
1385
]
],
[
[
1371,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
1371,
63,
1144
],
[
1144,
62,
1103
],
[
1103,
23,
1385
]
],
[
[
13... | [
[
[
"Chromium picolinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Chromium picolinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglin... | Chromium picolinate may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chromium picolinate may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01028 | DB09135 | 1,332 | 1,211 | [
"DDInter1179",
"DDInter967"
] | Methoxyflurane | Ioxilan | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
1332,
25,
1211
]
],
[
[
1332,
24,
712
],
[
712,
25,
1211
]
],
[
[
1332,
63,
372
],
[
372,
25,
1211
]
],
[
[
1332,
64,
629
],
[
629,
... | [
[
[
"Methoxyflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Methoxyflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsal... | Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioxilan
Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may... |
DB00285 | DB00748 | 1,100 | 662 | [
"DDInter1927",
"DDInter297"
] | Venlafaxine | Carbinoxamine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1100,
24,
662
]
],
[
[
1100,
24,
28
],
[
28,
40,
662
]
],
[
[
1100,
24,
1594
],
[
1594,
24,
662
]
],
[
[
1100,
6,
6017
],
[
6017,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that co... |
DB00570 | DB01394 | 147 | 1,554 | [
"DDInter1936",
"DDInter431"
] | Vinblastine | Colchicine | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
147,
24,
1554
]
],
[
[
147,
6,
4973
],
[
4973,
45,
1554
]
],
[
[
147,
34,
16974
],
[
16974,
46,
1554
]
],
[
[
147,
7,
10996
],
[
10996... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Vinblastine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Vinblastine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Colchicine (Compound)
Vinblastine (Compound) binds TUBB6 (Gene) and Vinblastine (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is upregulated by Colchicine (Compound)
Vinblastine (Compound) upregulates MICAL1 (Gene) and MICAL1 (Gene) is upregu... |
DB01364 | DB03754 | 22 | 1,400 | [
"DDInter650",
"DDInter1883"
] | Ephedrine | Tromethamine | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th e... | Moderate | 1 | [
[
[
22,
24,
1400
]
],
[
[
22,
63,
959
],
[
959,
23,
1400
]
],
[
[
22,
63,
1360
],
[
1360,
24,
1400
]
],
[
[
22,
24,
93
],
[
93,
24,
... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tromethamine"
]
],
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Mecamylamine and Mecamyla... |
DB01118 | DB11569 | 33 | 1,093 | [
"DDInter76",
"DDInter1003"
] | Amiodarone | Ixekizumab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
33,
24,
1093
]
],
[
[
33,
63,
608
],
[
608,
24,
1093
]
],
[
[
33,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
33,
64,
467
],
[
467,
24... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekin... |
DB06203 | DB14276 | 1,002 | 1,631 | [
"DDInter51",
"DDInter1892"
] | Alogliptin | Turmeric | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
1002,
24,
1631
]
],
[
[
1002,
63,
473
],
[
473,
24,
1631
]
],
[
[
1002,
1,
1281
],
[
1281,
24,
1631
]
],
[
[
1002,
24,
1296
],
[
1296,... | [
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
... | Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Turmeric
Alogliptin (Compound) resembles Linagliptin (Compound) and Linagliptin may cause a moderate interaction that cou... |
DB00635 | DB01023 | 1,573 | 409 | [
"DDInter1515",
"DDInter716"
] | Prednisone | Felodipine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Moderate | 1 | [
[
[
1573,
24,
409
]
],
[
[
1573,
63,
376
],
[
376,
40,
409
]
],
[
[
1573,
63,
1428
],
[
1428,
1,
409
]
],
[
[
1573,
24,
336
],
[
336,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compound)
... |
DB00295 | DB06282 | 475 | 516 | [
"DDInter1244",
"DDInter1053"
] | Morphine | Levocetirizine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
475,
24,
516
]
],
[
[
475,
63,
701
],
[
701,
24,
516
]
],
[
[
475,
24,
614
],
[
614,
24,
516
]
],
[
[
475,
25,
1178
],
[
1178,
2... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine and D... |
DB00783 | DB13928 | 1,438 | 1,385 | [
"DDInter679",
"DDInter1660"
] | Estradiol | Semaglutide | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1438,
24,
1385
]
],
[
[
1438,
24,
891
],
[
891,
24,
1385
]
],
[
[
1438,
1,
559
],
[
559,
24,
1385
]
],
[
[
1438,
63,
1144
],
[
1144,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Estradiol (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could ex... |
DB01599 | DB09078 | 1,232 | 1,228 | [
"DDInter1523",
"DDInter1036"
] | Probucol | Lenvatinib | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1232,
24,
1228
]
],
[
[
1232,
62,
112
],
[
112,
23,
1228
]
],
[
[
1232,
63,
609
],
[
609,
24,
1228
]
],
[
[
1232,
24,
603
],
[
603,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clar... |
DB01410 | DB12825 | 423 | 1,375 | [
"DDInter375",
"DDInter1032"
] | Ciclesonide | Lefamulin | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
423,
24,
1375
]
],
[
[
423,
23,
659
],
[
659,
24,
1375
]
],
[
[
423,
62,
455
],
[
455,
24,
1375
]
],
[
[
423,
24,
214
],
[
214,
... | [
[
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Ciclesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
... | Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmetero... |
DB01149 | DB08820 | 851 | 1,478 | [
"DDInter1274",
"DDInter997"
] | Nefazodone | Ivacaftor | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
851,
25,
1478
]
],
[
[
851,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
851,
21,
29998
],
[
29998,
60,
1478
]
],
[
[
851,
25,
1135
],
[
1135,... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacafto... | Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Nefazodone (Compound) causes Hyperaesthesia (Side Effect) and Hyperaesthesia (Side Effect) is caused by Ivacaftor (Compound)
Nefazodone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol ma... |
DB01601 | DB13074 | 833 | 877 | [
"DDInter1089",
"DDInter1110"
] | Lopinavir | Macimorelin | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
833,
25,
877
]
],
[
[
833,
63,
770
],
[
770,
24,
877
]
],
[
[
833,
63,
485
],
[
485,
25,
877
]
],
[
[
833,
24,
144
],
[
144,
25,... | [
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomid... | Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pent... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.